Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Enlivex Therapeutics (ENLV)

Enlivex Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ENLV
DateTimeSourceHeadlineSymbolCompany
04/03/202521:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
04/03/202521:30GlobeNewswire Inc.Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetraâ„¢ Trial in Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
03/03/202513:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
03/03/202513:22GlobeNewswire Inc.Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
18/02/202511:22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
18/02/202511:20GlobeNewswire Inc.Enlivex Issues Urgent Statement on Fraudulent News DisseminationNASDAQ:ENLVEnlivex Therapeutics Ltd
14/02/202522:43Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ENLVEnlivex Therapeutics Ltd
11/12/202413:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
11/12/202413:30GlobeNewswire Inc.Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
03/12/202413:32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
03/12/202413:30GlobeNewswire Inc.Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
29/11/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
20/11/202413:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
20/11/202413:00GlobeNewswire Inc.Enlivex Adopts Bitcoin Treasury Reserve StrategyNASDAQ:ENLVEnlivex Therapeutics Ltd
14/11/202420:29Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ENLVEnlivex Therapeutics Ltd
14/11/202413:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
14/11/202413:00GlobeNewswire Inc.Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic ArthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
12/11/202413:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
12/11/202413:00GlobeNewswire Inc.Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
31/10/202420:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
30/10/202412:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
30/10/202412:00GlobeNewswire Inc.Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetraâ„¢ in Patients with OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
15/10/202410:03Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:ENLVEnlivex Therapeutics Ltd
26/09/202412:32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
26/09/202412:30GlobeNewswire Inc.Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
24/09/202412:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
24/09/202412:30GlobeNewswire Inc.Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
11/09/202412:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
30/08/202420:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
23/07/202412:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:ENLV